The Roles of Tissue Factor in Malignant Gliomas

This study has been completed.

Sponsor:

Collaborator:

Ontario Cancer Research Network

Information provided by:

Ontario Clinical Oncology Group (OCOG)

ClinicalTrials.gov Identifier:

NCT00201903

First received: September 13, 2005

Last updated: May 18, 2007

Last verified: May 2007

History of Changes

Tracking Information

First Received Date ^ICMJE

September 13, 2005

Last Updated Date

May 18, 2007

Start Date ^ICMJE

January 2004

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

Not Provided

Original Primary Outcome Measures ^ICMJE

Not Provided

Change History

Complete list of historical versions of study NCT00201903 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Not Provided

Original Secondary Outcome Measures ^ICMJE

Not Provided

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

The Roles of Tissue Factor in Malignant Gliomas

Official Title ^ICMJE

The Roles of Tissue Factor in Malignant Gliomas

Brief Summary

To explore the relationship between tissue factor levels, tumour progression, activation of blood coagulation and venous thromboembolism with malignant glioma

Detailed Description

To explore the relationship between tissue factor levels, tumour progression, activation of blood coagulation and venous thromboembolism with malignant glioma

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective

Target Follow-Up Duration

Not Provided

Biospecimen

Not Provided

Sampling Method

Not Provided

Study Population

Not Provided

Condition ^ICMJE

Venous Thromboembolism
Brain Tumors

Intervention ^ICMJE

Not Provided

Study Group/Cohort (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

October 2006

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Inclusion Criteria:

participation in PRODIGE
adult patients
newly diagnosed, biopsy-confirmed grade III/IV malignant gliomas
undergone craniotomy or stereotactic biopsy > 2 days and < 4 weeks before

Exclusion Criteria:

have known hereditary thrombophilia
are receiving experimental antiangiogenic therapy

Gender

Both

Ages

18 Years and older

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

United States, Canada

Administrative Information

NCT Number ^ICMJE

NCT00201903

Other Study ID Numbers ^ICMJE

OCOG-2003-TFsubstudy

Has Data Monitoring Committee

Yes

Responsible Party

Not Provided

Study Sponsor ^ICMJE

Ontario Clinical Oncology Group (OCOG)

Collaborators ^ICMJE

Ontario Cancer Research Network

Investigators ^ICMJE

Study Chair:	Agnes Lee, MD	Hamilton Health Sciences and McMaster University
Principal Investigator:	William Geerts, MD	Sunnybrook Health Sciences Centre
Principal Investigator:	Mark Levine, MD	Ontario Clinical Oncology Group (OCOG)
Principal Investigator:	James Perry, MD	Toronto Sunnybrook Regional Cancer Centre
Principal Investigator:	Janusz Rak	Hamilton Health Sciences and McMaster University
Principal Investigator:	Jeffrey Weitz, MD	Hamilton Health Sciences and McMaster University

Information Provided By

Ontario Clinical Oncology Group (OCOG)

Verification Date

May 2007

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top